GAMEC-II, Risk-adapted Protocol for Relapsed Germ Cell Tumours (GCT)

NCT06309732 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Testicular Neoplasms

Interventions

DRUG: Pegfilgrastim
DRUG: Dactinomycin
DRUG: Methotrexate
DRUG: Etoposide
DRUG: Cisplatin
DRUG: Epirubicin

Sponsor

Queen Mary University of London